TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7806038

Group type: EXPERIMENTAL
Intervention: Interferon alfa (10 MU/m2 three times weekly for 12 weeks)
Number of subjects: 50
Study: 1941387

Group type: EXPERIMENTAL
Intervention: Erythropoietin (200 units/kg every other day for 10 doses)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Erythrocyte transfusion
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 19
Study: 7079889

Group type: EXPERIMENTAL
Intervention: Low-pressure continuous-flow water irrigation system
Number of subjects: 14

Group type: COMPARATOR
Intervention: Routine method of intermittent bladder emptying
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Simple suprapubic shunt
Number of subjects: 14
Study: 30856124

Group type: EXPERIMENTAL
Intervention: Soymilk (SMS; n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PLA; n = 11)
Number of subjects: 22
Study: 30573783

Group type: EXPERIMENTAL
Intervention: Real RF exposure (UMTS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Real RF exposure (LTE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 60
Study: 26724252

Group type: EXPERIMENTAL
Intervention: Cooperative group
Number of subjects: 3

Group type: COMPARATOR
Intervention: Individual group
Number of subjects: 3
Study: 24753225

Group type: EXPERIMENTAL
Intervention: Cognitive-emotional training paradigm (emotional faces memory task, EFMT) involving eight sessions over 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Active control condition (control training, CT)
Number of subjects: 21
Study: 21410633

Group type: EXPERIMENTAL
Intervention: da Vinci S robot
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard da Vinci robot
Number of subjects: 100
Study: 19670810

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg twice a day for 3 days)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Phosphomycin (a single 3.0 g dose)
Number of subjects: 108
Study: 17855282

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention modelled on the WHO/UNICEF baby friendly hospital initiative
Number of subjects: 17046

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 17046
Study: 15239141

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 0.2 g/kg body weight daily + Soybean oil (SO) 0.8 g/kg body weight daily (n = 24)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Soybean oil (SO) 1.0 g/kg body weight daily (n = 20)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) treatment
Number of subjects: 44
Study: 11514082

Group type: EXPERIMENTAL
Intervention: Dysfunctional patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonally distressed patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adaptive copers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All subgroups
Number of subjects: 0
Study: 9591521

Group type: EXPERIMENTAL
Intervention: tolcapone 100 mg three times daily
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: tolcapone 200 mg three times daily
Number of subjects: 298

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 298
Study: 7887018

Group type: EXPERIMENTAL
Intervention: BCG plus killed promastigotes (group A)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: BCG alone (group B)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Killed promastigotes alone (group C)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Diluents control (placebo, group D)
Number of subjects: 208
Study: 2974781

Group type: EXPERIMENTAL
Intervention: NPH insulin by means of a pen injector (Insuject‐X)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional syringes
Number of subjects: 50
Study: 31267292

Group type: EXPERIMENTAL
Intervention: Fluoxetine (mean dose 11.8 mg/day)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 158
Study: 30379222

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy group with 8h of intensive treatment to maximize oxygen delivery
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study: 27460471

Group type: EXPERIMENTAL
Intervention: Oral health optimized diet (low in carbohydrates, rich in Omega‐3 fatty acids, vitamins C and D, antioxidants, and fiber) for four weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no dietary change)
Number of subjects: 15
Study: 25673173

Group type: EXPERIMENTAL
Intervention: Inferior hypogastric plexus blockade
Number of subjects: 117

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 117
Study: 23312487

Group type: EXPERIMENTAL
Intervention: Isoflavone vaginal gel 4% (1g/day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen cream (0.3mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 90
Study: 20492051

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 60
Study: 18276723

Group type: EXPERIMENTAL
Intervention: Chest physical therapy plus standard treatment for pneumonia
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard treatment for pneumonia alone
Number of subjects: 98
Study: 17065118

Group type: EXPERIMENTAL
Intervention: NeuFlex implants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sutter implants
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 12967810

Group type: EXPERIMENTAL
Intervention: Argon laser iridotomy (Ar-LI group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Argon combined with YAG laser iridotomy (Ar-YAG-LI group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study: 10687884

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 876
Study: 9324343

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with PBSC support (Regimen A: etoposide, carboplatinum 1.95 g/m2, cyclophosphamide 5 g/m2, thiotepa 300 mg/m2; Regimen A': carmustine 600 mg/m2 replacing cyclophosphamide; Regimen B: etoposide, carboplatinum 1.95 g/m2, cyclophosphamide 7 g/m2, thiotepa 900 mg/m2)
Number of subjects: 10
Study: 1437030

Group type: EXPERIMENTAL
Intervention: Flat occlusal splint
Number of subjects: 51

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 51
Study: 3549397

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (Biken) containing F-HA and pertussis toxin toxoid; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain whole cell vaccine; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (Biken) with aluminium phosphate as adjuvant; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 31295174

Group type: EXPERIMENTAL
Intervention: Protease inhibitor-based antiretroviral treatment (ART) regimen
Number of subjects: 3333

Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine
Number of subjects: 3333

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) alone
Number of subjects: 3333

Group type: EXPERIMENTAL
Intervention: Both ART regimens (protease inhibitor-based and ZDV)
Number of subjects: 3333

Group type: EXPERIMENTAL
Intervention: Demographic and clinical factors
Number of subjects: 3333
Study: 29480886

Group type: EXPERIMENTAL
Intervention: Mindfulness-based video exercise
Number of subjects: 125

Group type: COMPARATOR
Intervention: Attention placebo control (educational pamphlet)
Number of subjects: 125
Study: 26342472

Group type: EXPERIMENTAL
Intervention: 24 months of dual antiplatelet therapy (DAPT)
Number of subjects: 1754

Group type: COMPARATOR
Intervention: 6 months of dual antiplatelet therapy (DAPT)
Number of subjects: 1754
Study: 24712378

Group type: EXPERIMENTAL
Intervention: 15 g/d yellow pea fibre
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 30
Study: 22668852

Group type: EXPERIMENTAL
Intervention: Dietary pattern intervention (3 dietary patterns)
Number of subjects: 206
Study: 20598833

Group type: EXPERIMENTAL
Intervention: Nicotine patch (NP)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Both groups (NP and placebo)
Number of subjects: 424
Study: 17569128

Group type: EXPERIMENTAL
Intervention: lamivudine, interferon alpha (IFN‐alpha 2b), or sequential therapy with lamivudine-IFN‐alpha 2b for 48 weeks
Number of subjects: 71
Study: 15305694

Group type: EXPERIMENTAL
Intervention: Highly Active AntiRetroviral Therapy (HAART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 0
Study: 11583526

Group type: EXPERIMENTAL
Intervention: 4-s standard
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 8-s standard
Number of subjects: 3
Study: 9794107

Group type: EXPERIMENTAL
Intervention: Homozygous for the codon 354 variant (GIP receptor variant)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Wild-type receptor
Number of subjects: 451
Study: 7641350

Group type: EXPERIMENTAL
Intervention: Hirulog 0.02 mg.kg‐1.h‐1
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Hirulog 0.25 mg.kg‐1.h‐1
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Hirulog 0.5 mg.kg‐1.h‐1
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Hirulog 1.0 mg.kg‐1.h‐1
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Hirulog (all doses)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 410
Study: 2619334

Group type: EXPERIMENTAL
Intervention: Combined wooden spatula and cytobrush
Number of subjects: 75

Group type: COMPARATOR
Intervention: Combined wooden spatula and cotton swab
Number of subjects: 75
Study: 319815

Group type: EXPERIMENTAL
Intervention: Doxapram 80 mg i.v.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no doxapram)
Number of subjects: 100
Study: 29505434

Group type: EXPERIMENTAL
Intervention: Tresident (polyvinylsiloxane)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Orthoprint (irreversible hydrocolloid)
Number of subjects: 20
Study: 28332025

Group type: EXPERIMENTAL
Intervention: Normobaric 'Live High-Train Low' (LHTL) for 6 weeks at altitudes of 2500-3500 m
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (normoxia) for 6 weeks
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Normobaric 'Live High-Train Low' (LHTL) for 6 weeks
Number of subjects: 7
Study: 25171883

Group type: EXPERIMENTAL
Intervention: 40 mg of triamcinolone at the borders of the wall lacerations during each dilation session
Number of subjects: 19

Group type: COMPARATOR
Intervention: Dilation alone (control)
Number of subjects: 19
Study: 23305566

Group type: EXPERIMENTAL
Intervention: Weekly Group - 30 mg elemental iron weekly for 10 months (40 doses)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cyclical Group - 30 mg elemental iron daily for 20 days, two cycles separated by four months (40 doses total)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control Group - Not applicable
Number of subjects: 99
Study: 21161264

Group type: EXPERIMENTAL
Intervention: HIT (B) with bicarbonate
Number of subjects: 11

Group type: COMPARATOR
Intervention: HIT (P) with placebo
Number of subjects: 11

Group type: COMPARATOR
Intervention: HVT (high-volume endurance training)
Number of subjects: 11
Study: 19109444

Group type: EXPERIMENTAL
Intervention: CPT + FST
Number of subjects: 30

Group type: COMPARATOR
Intervention: CPT
Number of subjects: 30

Group type: COMPARATOR
Intervention: CPT + CPT
Number of subjects: 30
Study: 17954153

Group type: EXPERIMENTAL
Intervention: Taguchi technique
Number of subjects: 277

Group type: COMPARATOR
Intervention: Lich-Gregoir technique
Number of subjects: 277
Study: 16078092

Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 11823654

Group type: EXPERIMENTAL
Intervention: Combined clinical and imaging information (NIH Stroke Scale + CT infarct volume)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Clinical information alone (NIH Stroke Scale)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Imaging information alone (CT infarct volume)
Number of subjects: 201
Study: 10346551

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study: 7720760

Group type: EXPERIMENTAL
Intervention: 5 mg sublingual ISDN
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 300-kcal, 300-ml mixed liquid meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5 mg sublingual ISDN followed by meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: meal followed by 5 mg sublingual ISDN
Number of subjects: 24
Study: 2188182

Group type: EXPERIMENTAL
Intervention: Diet plus insulin (20 units NPH and 10 units regular)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 108
Study: 7434206

Group type: EXPERIMENTAL
Intervention: Cerium nitrate-silver sulfadiazine cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Silver sulfadiazine cream
Number of subjects: 60
Study: 30260366

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 43
Study: 27664457

Group type: EXPERIMENTAL
Intervention: Wormwood tea (bitter group; n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Water (control group; n = 19)
Number of subjects: 39
Study: 25876430

Group type: EXPERIMENTAL
Intervention: High-intensity laser irradiation (HILl)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 24481893

Group type: EXPERIMENTAL
Intervention: Video presentation
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Small group demonstration
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Self-directed slide show
Number of subjects: 289
Study: 21880242

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30/45 mg)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Combination of Pioglitazone and Ramipril (PIRA)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Ramipril (2.5/5 mg)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 149

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 149
Study: 19662998

Group type: EXPERIMENTAL
Intervention: BJVC
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 17536872

Group type: EXPERIMENTAL
Intervention: Nebulized tobramycin (TSI) 300mg/4mL
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 14996153

Group type: EXPERIMENTAL
Intervention: Intraoperative imprint cytology of sentinel nodes
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Immediate axillary clearance
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Delayed axillary clearance
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Lymph node involvement
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Successful identification of sentinel node
Number of subjects: 400
Study: 9868668

Group type: EXPERIMENTAL
Intervention: Protease inhibitors
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CD8+ lymphocyte proportion at baseline > 66%
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Increase in CD8+ lymphocyte proportion at month 1 > 5%
Number of subjects: 200
Study: 8032706

Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Teicoplanin
Number of subjects: 56
Study: 2588918

Group type: EXPERIMENTAL
Intervention: Spatula-Cytobrush method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spatula-cotton swab method
Number of subjects: 0
Study: 55586

Group type: EXPERIMENTAL
Intervention: Three biscuits daily each containing 10 g of ordinary miller's bran
Number of subjects: 59

Group type: COMPARATOR
Intervention: Wheat biscuits of a similar appearance (control group)
Number of subjects: 59
Study: 31153976

Group type: EXPERIMENTAL
Intervention: CONSORT guidelines
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: CONSORT extensions
Number of subjects: 1000
Study: 29224298

Group type: EXPERIMENTAL
Intervention: Gradual smoking cessation
Number of subjects: 314

Group type: COMPARATOR
Intervention: Abrupt smoking cessation
Number of subjects: 314
Study: 25027443

Group type: EXPERIMENTAL
Intervention: High-speed treadmill training (n = 30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Progressive treadmill training (n = 31)
Number of subjects: 61
Study: 23535230

Group type: EXPERIMENTAL
Intervention: Ultrasonographically guided arterial puncture (group 1)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional method (group 2)
Number of subjects: 74
Study: 21672343

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ondansetron 8 mg
Number of subjects: 90
Study: 18600436

Group type: EXPERIMENTAL
Intervention: Biased instructions and positive feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biased instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pre-identification feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative pre-identification feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive pre-identification feedback
Number of subjects: 0
Study: 16308544

Group type: EXPERIMENTAL
Intervention: DCBT4567‐Astha‐15
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Salbutamol (12 mg/day)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Salbutamol (12 mg/day) + Theophylline (200 mg/day)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 15617457

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg once daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 58
Study: 11500251

Group type: EXPERIMENTAL
Intervention: Progesterone (25, 50, 100 mg im)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Progesterone (100 mg im)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9257071

Group type: EXPERIMENTAL
Intervention: Modified Ratio Estimate (MRE) statistic applied to analyze data of vein grafts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Ratio Estimate (MRE) statistic
Number of subjects: 0
Study: 8342904

Group type: EXPERIMENTAL
Intervention: Prednisolone, 0.6 mg/kg/day for 2 weeks
Number of subjects: 18
Study: 3098340

Group type: EXPERIMENTAL
Intervention: Breast conservation (lumpectomy followed by radiotherapy)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 101
Study: 29246847

Group type: EXPERIMENTAL
Intervention: medical care
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: community‐based group exercise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: clinic‐based manual therapy and individualized exercise
Number of subjects: 50
Study: 27575024

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 400

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 400
Study: 25050337

Group type: EXPERIMENTAL
Intervention: Bee venom (BV) ointment applied locally over masseter muscles for 14 days during a 3-minute massage.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (vaseline) applied during a 3-minute massage.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bee venom (BV) ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (vaseline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.0005% BV ointment
Number of subjects: 0
Study: 22023069

Group type: EXPERIMENTAL
Intervention: Zinc 250mg administered concurrently with cephalexin 500mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zinc 250mg administered 3h before cephalexin 500mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Zinc 250mg administered 3h after cephalexin 500mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cephalexin 500mg alone
Number of subjects: 12
Study: 19935771

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) plus weekly paclitaxel
Number of subjects: 47

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone
Number of subjects: 47
Study: 18416586

Group type: EXPERIMENTAL
Intervention: pegylated interferon-alpha-2a 180 microg once weekly plus ribavirin 15 mg/kg/day
Number of subjects: 108

Group type: COMPARATOR
Intervention: pegylated interferon-alpha-2b 1.5 microg/kg once weekly plus ribavirin 15 mg/kg/day
Number of subjects: 108
Study: 15948518

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide tooth bleaching gel delivered on polyethylene film (HP)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 18% carbamide peroxide brush-applied liquid gel (CP)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: L*a*b* values from ShadeVision System for HP
Number of subjects: 59
Study: 14525628

Group type: EXPERIMENTAL
Intervention: Nasal mask
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Full-face mask
Number of subjects: 14
Study: 11869846

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (dalteparin)
Number of subjects: 71
Study: 10025296

Group type: EXPERIMENTAL
Intervention: Podiatric care group (individual counseling and primary prevention measures, n = 267)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Control group (written instructions only, n = 263)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Podiatric care group
Number of subjects: 530

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Podiatric care group and Control group
Number of subjects: 530
Study: 8142098

Group type: EXPERIMENTAL
Intervention: 24-gauge Sprotte needle
Number of subjects: 375

Group type: COMPARATOR
Intervention: 22-gauge Sprotte needle
Number of subjects: 375
Study: 3124203

Group type: COMPARATOR
Intervention: Standard clinic information and advice to quit smoking
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Standard clinic information and advice to quit plus the manual 'Freedom From Smoking in 20 Days'
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Standard clinic information and advice to quit plus the pregnancy-specific manual 'A Pregnant Woman's Self-Help Guide to Quit Smoking'
Number of subjects: 309